Current status of the pathogenesis, diagnosis, and treatment of sarcopenia in patients with liver cirrhosis
10.3969/j.issn.1001-5256.2022.01.033
- VernacularTitle:肝硬化肌少症的发病机制与诊疗现状
- Author:
Yuyi LIU
1
;
Dongfeng CHEN
1
;
Qixian YAN
1
Author Information
1. Department of Gastroenterology, Army Medical Center of PLA & Daping Hospital, Chongqing 400042, China
- Publication Type:Reviews
- Keywords:
Liver Cirrhosis;
Sarcopenia;
Therapeutics
- From:
Journal of Clinical Hepatology
2022;38(1):191-195
- CountryChina
- Language:Chinese
-
Abstract:
Sarcopenia is a common complication in patients with liver cirrhosis, with an incidence rate of up to 40%-70%, which increases the incidence rate of complications in patients with liver cirrhosis and seriously affects patients' quality of life and survival time. Sarcopenia in liver cirrhosis has a complex pathogenesis, and its clinical manifestations are easily ignored. No consensus has been reached on diagnostic criteria, and there are few targeted therapeutic drugs. Therefore, it should be taken seriously by clinician and the research on pathogenesis and therapeutic drugs should be strengthened.
